journal article·2023-06-13

Bioengineered Nanospores Selectively Blocking LC3-Associated Phagocytosis in Tumor-Associated Macrophages Potentiate Antitumor Immunity

Yunkai Shang, Haipeng Lu, Li Liao, Suxin Li, Hui Xiong, Jing Yao

ACS Nano· Volume 17· Issue 11
Publisher page

Abstract

Although cytotoxic treatments hold tremendous potential in boosting antitumor immunity, efferocytosis of tumor-associated macrophages (TAMs) could negatively remove apoptotic tumor cells through LC3-associated phagocytosis (LAP), resulting in inefficient tumor antigen presentation and immunosuppressive tumor microenvironment. To address this issue, we developed TAM-targeting nanospores (PC-CW) inspired by the predominant tropism of Rhizopus oryzae toward macrophages. To construct PC-CW, we disguised poly(sodium- p -styrenesulfonate) (PSS)-coated polyethylenimine (PEI)-shRNA nanocomplexes with the cell wall of R. oryzae conidia. LAP blockade by PC-CW delayed the degradation of engulfed tumor debris within TAMs, which not only enhanced antigen presentation but also initiated the domino effect of the antitumor immune response through STING signaling and TAM repolarization. Benefiting from this, PC-CW successfully sensitized the immune microenvironment and amplified CD8 + T cell responses following chemo-photothermal therapy, leading to substantial tumor growth control and metastasis prevention in tumor-bearing mouse models. The bioengineered nanospores represent a simple and versatile immunomodulatory strategy targeting TAMs for robust antitumor immunotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Phagocytosis and Immune Regulation · Immune cells in cancer · Autophagy in Disease and Therapy

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, Department of Pharmaceutics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, People’s Republic of China

Funding

State Key Laboratory of Natural Medicines · ?333 Project? of Jiangsu Province · Double First Class University Plan · Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University

References (54)

Show source-provided references
1. 10.1126/science.aad077910.1126/science.aad0779 ↗
2. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
3. 10.1021/acsnano.2c0359710.1021/acsnano.2c03597 ↗
4. 10.1016/j.immuni.2013.06.01410.1016/j.immuni.2013.06.014 ↗
5. 10.1002/advs.20180186810.1002/advs.201801868 ↗
6. 10.1038/s41551-020-0599-510.1038/s41551-020-0599-5 ↗
7. 10.1038/nri.2017.910.1038/nri.2017.9 ↗
8. 10.1016/j.canlet.2018.08.02810.1016/j.canlet.2018.08.028 ↗
9. 10.1016/j.immuni.2020.01.01410.1016/j.immuni.2020.01.014 ↗
10. 10.1038/s41580-020-0232-110.1038/s41580-020-0232-1 ↗
11. 10.1038/nature2013810.1038/nature20138 ↗
12. 10.4049/jimmunol.190093010.4049/jimmunol.1900930 ↗
13. 10.1016/j.immuni.2013.09.01410.1016/j.immuni.2013.09.014 ↗
14. 10.1016/j.cell.2018.08.06110.1016/j.cell.2018.08.061 ↗
15. 10.1038/s41577-019-0240-610.1038/s41577-019-0240-6 ↗
16. 10.1073/pnas.111342110810.1073/pnas.1113421108 ↗
17. 10.1016/j.cell.2019.05.05610.1016/j.cell.2019.05.056 ↗
18. 10.3389/fonc.2020.0129810.3389/fonc.2020.01298 ↗
19. 10.1073/pnas.150427611210.1073/pnas.1504276112 ↗
20. 10.1038/s41590-019-0346-910.1038/s41590-019-0346-9 ↗
21. 10.1038/s41467-020-15404-810.1038/s41467-020-15404-8 ↗
22. 10.3390/cancers1207198710.3390/cancers12071987 ↗
23. 10.1038/nrclinonc.2016.21710.1038/nrclinonc.2016.217 ↗
24. 10.1038/ncb319210.1038/ncb3192 ↗
25. 10.1038/ncb184610.1038/ncb1846 ↗
26. 10.1038/nrc.2017.5310.1038/nrc.2017.53 ↗
27. 10.1016/j.ijfoodmicro.2017.06.01210.1016/j.ijfoodmicro.2017.06.012 ↗
28. 10.1038/s41467-018-05820-210.1038/s41467-018-05820-2 ↗
29. 10.1021/acs.nanolett.9b0500810.1021/acs.nanolett.9b05008 ↗
30. 10.3389/fmicb.2019.0046910.3389/fmicb.2019.00469 ↗
31. 10.1016/j.ijpharm.2020.11968210.1016/j.ijpharm.2020.119682 ↗
32. 10.1016/S0044-328X(79)80001-X10.1016/S0044-328X(79)80001-X ↗
33. 10.1038/nnano.2014.20810.1038/nnano.2014.208 ↗
34. Bouchara J. P. · European Journal of Cell Biology · 1996 · 70 · 76
35. 10.1128/IAI.73.2.778-783.200510.1128/IAI.73.2.778-783.2005 ↗
36. 10.1038/s41392-021-00544-010.1038/s41392-021-00544-0 ↗
37. 10.1021/mp200611d10.1021/mp200611d ↗
38. 10.1002/adma.20180574010.1002/adma.201805740 ↗
39. 10.1038/s41565-021-00988-z10.1038/s41565-021-00988-z ↗
40. 10.4049/jimmunol.171.9.456910.4049/jimmunol.171.9.4569 ↗
41. 10.1038/nm.431410.1038/nm.4314 ↗
42. 10.1038/nature1007110.1038/nature10071 ↗
43. 10.4049/jimmunol.150115810.4049/jimmunol.1501158 ↗
44. 10.1038/nature2597410.1038/nature25974 ↗
45. 10.1002/cpcb.10410.1002/cpcb.104 ↗
46. 10.1038/s41577-019-0127-610.1038/s41577-019-0127-6 ↗
47. 10.1084/jem.2002189010.1084/jem.20021890 ↗
48. 10.1016/j.intimp.2019.03.03210.1016/j.intimp.2019.03.032 ↗
49. 10.1016/j.immuni.2017.07.01610.1016/j.immuni.2017.07.016 ↗
50. 10.1091/mbc.e14-05-096710.1091/mbc.e14-05-0967 ↗
51. 10.1016/j.apsb.2020.07.01310.1016/j.apsb.2020.07.013 ↗
52. 10.1126/sciadv.aaz446210.1126/sciadv.aaz4462 ↗
53. 10.1002/advs.20210383610.1002/advs.202103836 ↗
54. 10.1038/nm109310.1038/nm1093 ↗